Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice
08 déc. 2022 12h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Oncotelic Reports that It's Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma
13 févr. 2019 09h15 HE
|
Oncotelic Inc
Phase 2 Clinical Data Presented at 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision MedicineOT-101 exhibited promising single agent clinical activity as second...